Adagene of Suzhou Files for $125 Million US IPO
January 21, 2021 at 06:32 AM EST
Adagene, a Suzhou immunotherapy company, plans to raise up to $125 million in a US IPO on the NASDAQ Exchange. The company uses a computational AI-based discovery platform that studies the motion of proteins and their dynamic interactions to discover novel epitopes of drug targets, differentiating Adagene's candidates. It has novel antibodies in China and US trials that target CD137 in advanced solid tumors and non-Hodgkin's lymphoma, and. a masked anti-CTLA-4 mAb engineered for better safety by avoiding off-target activation. More details.... Share this with colleagues: // //
